Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus XELOX conversion therapy for advanced unresectable gastric or gastroesophageal junction adenocarcinoma
ChiCTR2500103024Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
cadonilimabcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500103024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103024.